Vaxart, Inc. (VXRT)
| Market Cap | 121.82M +49.5% |
| Revenue (ttm) | 243.07M +201.1% |
| Net Income | 38.59M |
| EPS | 0.16 |
| Shares Out | 242.84M |
| PE Ratio | 3.10 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 227,645 |
| Open | 0.5040 |
| Previous Close | 0.5033 |
| Day's Range | 0.4901 - 0.5083 |
| 52-Week Range | 0.3050 - 0.8449 |
| Beta | 1.07 |
| Analysts | Strong Buy |
| Price Target | 3.33 (+563.81%) |
| Earnings Date | Aug 6, 2026 |
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for VXRT stock is "Strong Buy." The 12-month stock price target is $3.33, which is an increase of 563.81% from the latest price.
News
Vaxart granted European patent covering oral norovirus vaccine through 2036
Vaxart (VXRT) announced that the European Patent Office formally published the grant of European Patent No. 3791859 effective August 26. This patent further protects core intellectual property for Vax...
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European markets European Patent ...
Vaxart Earnings Call Transcript: Q2 2026
Positive 12-month safety data from the COVID-19 Sentinel cohort validated the oral pill platform, while BARDA funding enables deeper analytics. Revenue declined year-over-year, but cost controls improved net loss. Main COVID-19 trial data is expected in H1 2027.
Vaxart Earnings release: Q2 2026
Vaxart released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Vaxart Quarterly report: Q2 2026
Vaxart has published its Q2 2026 quarterly earnings report on August 7, 2026.
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
Company to report second quarter 2026 financial results on August 6 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company de...
Vaxart Slides: Corporate presentation
Vaxart has posted slides in relation to its latest quarterly earnings report, which was published on July 29, 2026.
Vaxart to Participate in BTIG Biotechnology Conference 2026
SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprieta...
Vaxart Announces Results of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pi...
Vaxart Transcript: AGM 2026
The meeting approved director elections and auditor ratification, but the say on pay proposal failed. Management addressed shareholder concerns about share price, reverse split, and pipeline progress, emphasizing ongoing partnerships and a cash runway through Q2 2027.
Vaxart reports data from sentinel safety cohort of oral COVID-19 vaccine trial
Vaxart (VXRT) announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the company’s oral pill COVID-19 vaccine candidate against ...
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on July 6, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart enters cooperation agreement with stockholder group
Vaxart (VXRT) announced a resolution to the proxy contest in connection with the company’s 2026 annual meeting of stockholders. Vaxart will initiate a search for an additional independent director to…
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on July 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Details Strategic Actions Taken by the Board to Advance the Company's Pipeline and Drive Value Creation Vaxart's Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Gro...
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart receives contract modification for oral vaccine trial funding
Vaxart (VXRT) announced a contract modification releasing additional funding from the Biomedical Advanced Research and Development Authority to support its ongoing Phase 2b oral vaccine trial. Under t...
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of Key Tri...
Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
Urges Stockholders to Vote “FOR” ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., ...